Afamelanotide · source year
6 selected, source-linked Afamelanotide records carrying a 2019 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
6 selected records.
3 represented types.
6 distinct public records.
Cited chronology
Regulatory
DailyMed lists Structured Product Labeling version 1 for the reviewed Afamelanotide label family with a published date of 2019-12-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Literature metadata
PeptideScanner retained PubMed bibliographic metadata for PMID 30517779 at 2026-07-30T20:44:20.583Z. PubMed recorded a metadata revision date of 2019-11-20 and an Entrez history date of 2018-12-06. PeptideScanner associated this retained record with the identity slug afamelanotide. These dates describe PubMed metadata history, not the article's original publication date.
Source: PubMed ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01097044 at 2026-07-30T20:44:36.694Z. Its registry update date was 2019-10-28, and PeptideScanner's reviewed identity mapping was afamelanotide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04053270 at 2026-07-30T20:44:36.678Z. Its registry update date was 2019-10-10, and PeptideScanner's reviewed identity mapping was afamelanotide.
Source: ClinicalTrials.gov ↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for NDA 210797 with status AP dated 2019-10-08, and names afamelanotide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT01605136 at 2026-07-30T20:45:58.280Z. Its registry update date was 2019-09-19, and PeptideScanner's reviewed identity mapping was afamelanotide.
Source: ClinicalTrials.gov ↗